The recent cIMPACT-NOW update has recommended that for IDH wild-type gliomas, even if the histology suggests low grade, if accompanied by at least one of the three high-risk events, including chromosome 7gain/10loss, TERT promoter mutation, and EGFR amplification, they should be assigned to grade IV (Brat et al., 2018). This evidence concerns the gene EGFR and central nervous system cancer.